These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system. Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451 [TBL] [Abstract][Full Text] [Related]
4. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT). Reinartz J; Link J; Todd RF; Kramer MD Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643 [TBL] [Abstract][Full Text] [Related]
8. Functional involvement of urokinase-type plasminogen activator receptor in pemphigus acantholysis. Xue W; Hashimoto K; Toi Y J Cutan Pathol; 1998 Oct; 25(9):469-74. PubMed ID: 9821076 [TBL] [Abstract][Full Text] [Related]
9. mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. Baird J; Lazarus GS; Belin D; Vassalli JD; Busso N; Gubler P; Jensen PJ J Invest Dermatol; 1990 Nov; 95(5):548-52. PubMed ID: 2121833 [TBL] [Abstract][Full Text] [Related]
10. An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid. Venning VA; Wojnarowska F; Cederholm-Williams S Clin Exp Dermatol; 1993 Mar; 18(2):119-23. PubMed ID: 8481985 [TBL] [Abstract][Full Text] [Related]
11. Retinoic acid upregulates the plasminogen activator system in human epidermal keratinocytes. Braungart E; Magdolen V; Degitz K J Invest Dermatol; 2001 May; 116(5):778-84. PubMed ID: 11348470 [TBL] [Abstract][Full Text] [Related]
12. Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes. Schmidt E; Wehr B; Tabengwa EM; Reimer S; Bröcker EB; Zillikens D Clin Exp Immunol; 2004 Mar; 135(3):497-504. PubMed ID: 15008985 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis. Gissler HM; Frank R; Kramer MD Br J Dermatol; 1993 Jun; 128(6):612-8. PubMed ID: 7687853 [TBL] [Abstract][Full Text] [Related]
14. A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration. McNeill H; Jensen PJ Cell Regul; 1990 Oct; 1(11):843-52. PubMed ID: 1965151 [TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface. Ragno P; Montuori N; Rossi G Eur J Biochem; 1995 Oct; 233(2):514-9. PubMed ID: 7588796 [TBL] [Abstract][Full Text] [Related]
16. Differential expression of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester. Lund LR; Eriksen J; Ralfkiaer E; Rømer J J Invest Dermatol; 1996 Apr; 106(4):622-30. PubMed ID: 8617995 [TBL] [Abstract][Full Text] [Related]
18. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947 [TBL] [Abstract][Full Text] [Related]
19. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. Cubellis MV; Wun TC; Blasi F EMBO J; 1990 Apr; 9(4):1079-85. PubMed ID: 2157592 [TBL] [Abstract][Full Text] [Related]